CIRB Studies

Below is the current list of studies covered by the CIRB. Participants should refer to ClinicalTrials.gov for general information about clinical trials. Institutions should refer to the Clinical Trials Support Unit (CTSU) website  for enrollment requirements and accrual status information. 

Study documents approved after July 1, 2013 are available to participating institutions for covered studies on the CTSU website. To request documents approved before July 1, 2013, participating institutions can contact the CIRB Helpdesk.

Review CIRB
Study Number Network Study Title CIRB
10264 ETCTN The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. A Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Adult CIRB - Early Phase Emphasis
10266 ETCTN A Phase II Multi-Institutional Trial to Evaluate Prostate Specific Membrane Antigen (PSMA)-Based PET Imaging of High Risk Prostate Cancer Adult CIRB - Early Phase Emphasis
10268 ETCTN Randomized Phase II Trial of Topotecan plus M6620 (VX-970) vs. Topotecan alone in Patients with Relapsed Small-Cell Lung Cancer Adult CIRB - Early Phase Emphasis
10272 NCORP-National Institutes of Health A Phase II Multi-Institutional Trial to Evaluate Prostate Specific Membrane Antigen (PSMA)-Based PET Imaging of High Risk Prostate Cancer Adult CIRB - Late Phase Emphasis
10273 ETCTN A Phase 1 Study of M3814 in combination with MEC in Patients with Relapsed or Refractory Acute Myeloid Leukemia Adult CIRB - Early Phase Emphasis
10276 ETCTN A Phase I/II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies Adult CIRB - Early Phase Emphasis
10285 ETCTN Phase 1/2 Study of an EZH2 inhibitor (tazemetostat) in combination with dual BRAF/MEK inhibition in patients with BRAF-mutated metastatic melanoma who progressed on prior BRAF/MEK inhibitor therapy Adult CIRB - Early Phase Emphasis
10287 ETCTN A randomized Phase I/II trial of fulvestrant and abemaciclib in combination with copanlisib (FAC) versus fulvestrant and abemaciclib alone (FA) for endocrine-resistant, hormone receptor positive, HER2 negative metastatic breast cancer (FAC vs FA) Adult CIRB - Early Phase Emphasis
10291 ETCTN A Phase 1b Study of M6620 in Combination with Radiation Therapy to Overcome Therapeutic Resistance in Chemotherapy Resistant Triple Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer Adult CIRB - Early Phase Emphasis
10292 ETCTN DURVA+ : Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody MEDI4736 (durvalumab) in Combination with Chemotherapy in Patients with Advanced Solid Tumors Adult CIRB - Early Phase Emphasis